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Abstract 
Introduction 
Increasing physical activity is associated with health benefits. Reduced physical activity has 
been noted in sarcoidosis, particularly where fatigue co-exists. Monitoring physical activity 
is possible with wrist-worn devices. This study compared two available devices to determine 
patient preference and compare wear-time, with a secondary outcome of comparing device 
outputs with fatigue scores. 
Methods 
Patients with sarcoidosis wore two wrist-worn activity monitors (GENEActiv actiwatch and 
Actigraph GT3X-bt) separately for seven days each. Participants were randomly allocated to 
receive either device first. Participants completed the Fatigue Assessment Scale (FAS) 
questionnaire immediately before wearing the first device. All participants completed a 
questionnaire of their perception regarding each device after the wear period. Data from 
the devices was analysed for total wear time, time spent in moderate or vigorous activity 
(MVPA) and for time spent in sedentary behaviours. 
Results 
Twelve patients with sarcoidosis were included. The GENEActiv device was preferred by ten 
(83.3%) participants. Wear time was greater with the GENEActiv device (1354 minutes/day 
vs 1079 minutes/day). Time spent in MVPA was slightly higher when recorded by the 
GENEActiv compared with the Actigraph. Moderately strong correlation was seen between 
FAS scores and sedentary time (r= -0.554), light activity (r= -0.585) and moderate activity (r= 
0.506). 
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Discussion 
A clear preference was demonstrated for the GENEActiv. This was reflected in higher wear 
time and suggests the device can be comfortably worn 24 hours per day. Data from this 
small cohort also suggests there is correlation between fatigue and activity scores in 
patients with sarcoidosis. 
 
249 words 
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Introduction 
Increasing physical activity is associated with a wide-range of health benefits(1) and 
therefore assessing physical activity is important when evaluating interventions to support 
individuals to be active. Unfortunately, activity questionnaires are associated with recall bias 
and therefore other methods, including the use of accelerometry-based activity monitors, 
are required.(2). Accelerometers have been shown to produce comparable results to 
double-labelled water, the gold-standard measurement of energy expenditure, and can 
provide information on activity patterns rather than total energy expenditure over a set 
period(3). Some accelerometers are also able to measure sedentary behaviours, comparable 
to the gold-standard measure of inclinometers(4-6).  
Activity monitors can either be worn proximally on the hip or upper arm, or distally on the 
wrist or ankle. The wrist position is associated with a reduction in accuracy when classifying 
activity intensity compared with the hip position, potentially due to constraint of movement 
at the wrist when performing certain activities(7). However, wrist-worn devices benefit from 
being more acceptable to participants may lead to better compliance and improved wear 
time(8). For this reason, the UK Biobank and the USA National Health and Nutrition 
Examination Survey (NHANES) now use wrist-worn devices to measure activity in 
participants. There are a number of wrist-worn devices available, yet it is unclear how much 
impact the individual design has on the comfort of wearing the device, as well as the 
subsequent effect on wear time.  
Sarcoidosis is a multi-system, granulomatous disease of unknown origin(9). It can affect any 
organ or system within the body and can present with a range of symptoms that can persist 
in a chronic form(10, 11). A large number of patients with chronic disease suffer non-specific 
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manifestations, including fatigue in up to 80% of sufferers(12). It has been suggested that 
activity levels are reduced in patients with sarcoidosis, particularly when suffering from 
fatigue(13), and that improving physical activity can improve fatigue scores(14, 15). 
Although the link between sedentary behaviours (defined as sitting or lying with low energy-
expenditure) and fatigue has not been investigated in patients with sarcoidosis, an inverse 
correlation between them has been seen in other conditions where fatigue is a prominent 
symptom, such as fibromyalgia(16) and rheumatoid arthritis(17). Furthermore, it has 
previously been suggested that when considering choice of device for future studies within 
a patient group that a pilot study be performed to determine the  ideal accelerometer 
device(18). Sarcoidosis patients have lower levels of activity than health individuals, even 
when the disease is in remission (13); it is therefore important to compare how potential 
devices will perform.  
This study investigates the relative acceptability of two widely-used wrist-worn, 
accelerometry-based activity monitors, the GENEActiv original and the Actigraph GT3X-bt, in 
patients with sarcoidosis. These two devices are different in design but both output raw 
data which can be analysed in an identical fashion (5, 19). Both have also been shown to be 
able to measure sedentary behaviours(4, 5). The primary outcomes of interest are patient 
preferences relating to device comfort and wear time of the devices. The secondary 
outcomes of interest are patterns of activity and sedentary behaviours in these patients and 
the correlation between these outputs and the fatigue questionnaire scores.  
 
Methods 
Subjects 
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The study was undertaken at the Norfolk and Norwich University Hospital, in the UK. 
Patients with a diagnosis of sarcoidosis were eligible for inclusion. The requirement for a 
diagnosis of sarcoidosis was either (1) a previous biopsy confirming non-caseating 
granulomas consistent with sarcoidosis, or (2) previous discussion by multi-disciplinary 
interstitial lung disease meeting panel with consensus diagnosis of sarcoidosis. All 
participants must have been aged over 18 years old and able to provide written consent. 
Ethical approval for the study was gained from the South West – Central Bristol Research 
Ethics Committee, reference number 15/SW/0363. The trial was registered on 
clinicaltrials.gov, reference NCT02626897. 
Seventeen patients were approached to take part in this study; twelve consented to 
participate. All participants wore both devices for seven days each in a cross-over manner. 
The order in which the devices were worn was allocated randomly based on a computer-
generated code.  
Clinical Assessments 
Data regarding body mass index (BMI), forced expiratory volume in 1 second (FEV1), forced 
vital capacity (FVC) and FEV1/FVC ratio were taken from the most recent clinic attendance. 
Data was recorded on current immunosuppression use, organs affected by sarcoidosis 
(stratified into pulmonary and extrapulmonary disease), and duration since diagnosis. All 
participants completed the Fatigue Assessment Scale (FAS) questionnaire, a ten question 
fatigue score with a maximum score of 50, as a measure of present levels of fatigue. The 
threshold for significant fatigue in the FAS score is 22 points or greater(20). 
Recording of device preference 
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All participants were asked to complete a survey documenting their impression of each 
device immediately after completing the period of wear for each. The questionnaire 
consisted of four 100mm visual analogue scales (VAS), with participants asked to mark on 
the 100mm scale their response to each of the following questions; (1) How comfortable 
was the device to wear? (2) How aware of it were you? (3) Would you have any objection to 
wearing it again? and (4) To what extent did it interfere with daily life? The VAS was scored 
by measuring the distance along a line from the left-hand side that the mark was made; a 
score of zero (0mm) referred to no problems for each question and a score of 100 (100mm) 
indicated severe or constant problems for each question. In addition to these four 
questions, participants were asked to complete a free-text box detailing any difficulties that 
were encountered with either device. 
Measurement of daily activity 
The two wrist-worn devices chosen for comparison were the GENEActiv original device 
(Activinsights, Cambridgeshire, UK) and the Actigraph GT3X-bt device (Actigraph, Pensacola, 
Florida, USA). The GENEActiv is a tri-axial, accelerometer-based activity monitor with a 
dynamic range of +/-8g (where g is equal to the gravitational pull of the earth), measuring 
43 x 40 x 13mm with a traditional plastic watch strap, and weighs 16 grams. The Actigraph 
GT3X-bt is also a tri-axial, accelerometry-based activity monitor with a dynamic range of +/-
6g, measuring 46 x 33 x 15mm with a Velcro-fixing strap, and weighs 19 grams. It has been 
widely used for both hip-worn and wrist-worn monitoring of activity. Because the primary 
outcome was determining in the acceptability and comfort of the devices, devices were 
worn separately over consecutive periods rather than simultaneously.  
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Each device was worn for seven days by each participant on their non-dominant wrist. 
Devices were initialised to record data over the seven day period and then returned via 
postal envelopes. They were set to record output from the accelerometer thirty times per 
second (i.e. sampling frequency 30Hz). Data was defined as ‘valid’ if the devices were worn 
for at least 10 hours per day for at least two weekdays and two weekend days; the number 
of patients meeting a higher threshold of 16 hours per day were also recorded in keeping 
with previous studies(21). Finally, the number of days with 24 hours of wear time within 
each recording period was noted. 
Activity data was analysed for both time spent in thresholds of activity (light, moderate and 
vigorous), as well as sedentary time. The mean accelerometer outputs by magnitude of 
wrist acceleration (Euclidean norm minus one-g, ENMO) per 24 hour period, during the least 
active 5 hours (L5) and most active 5 hours (M5) were calculated using the R-statistics 
package GGIR(22). Time spent in moderate or vigorous physical activity (MVPA) was 
calculated using the threshold of 100milli-g as has been used previously(19, 23) and is close 
to the specific device outputs signifying the threshold for moderate activity for both the 
GENEActiv (93.2milli-g) and Actigraph (100.6milli-g) devices, which have been established in 
previous data(24). MVPA was also calculated by ‘bout’ criteria as per WHO 
recommendations of activity occurring in bouts of at least ten minutes(1), using thresholds 
of more than 80% of any ten minute epoch spent above the 100milli-g threshold to be 
counted (MVPA10). Magnitude of difference in outputs between devices was calculated 
where minimum valid data was available from both devices for a participant. 
In addition to the output from GGIR, data from the preferred device (from the reported 
preference and total wear-time) was analysed for time spent in sedentary behaviours using 
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the sedentary sphere custom spreadsheet (available elsewhere(4)) after raw data from the 
devices had been converted into .csv format in 15-second epochs. Thresholds for activity 
vigour within this spreadsheet were taken from previous data by Esliger et al(25) and 
adjusted for the sampling frequency of the accelerometers, leading to differences in 
calculated time spent performing moderate or vigorous activity compared with the GGIR 
output.  
Statistical analysis 
All data analysis was undertaken by SPSS Statistics version 22 (IBM Corp, Illinois, USA). 
Comparison of device outputs and participant experience by each brand of accelerometer 
were undertaken. Correlations between FAS scores and time spent in sedentary behaviours 
and each threshold of activity was calculated using data from the preferred device.  
 
Results 
Demographic data for the participants are shown in Table 1. All participants had pulmonary 
sarcoidosis and five participants (41.7%) had extra-pulmonary disease. Five participants 
were receiving immunosuppression at the time of inclusion. Nine participants (75%) scored 
more than 21 on the FAS score, indicating significant fatigue.  
The GENEActiv device was preferred by ten (83.3%) of the participants in this study. The 
results from the VAS questionnaire regarding experience of the devices are shown in Figure 
1. Statistically significant differences (p<0.05) were seen between the devices, with the 
GENEActiv device being more highly rated by participants across all domains of comfort, 
awareness of the device, objection to wearing the device and interference with daily 
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activities. Comments against the Actigraph device included being ‘too bulky ‘(three 
participants) and the ‘Velcro strap was too uncomfortable’ (three participants). Despite this, 
all but one of these participants recorded minimum valid data.  Two participants disliked the 
GENEActiv device; one person found the strap uncomfortable and another developed a skin 
reaction to the strap, although both of these participants recorded sufficient data to be 
considered valid monitoring periods. Other comments against the GENEActiv referred to the 
lack of a watch-face on the device. 
Amongst the twelve patients who wore an accelerometer, 11 (91.7%) of the GENEActiv 
devices and 9 (75%) of the Actigraph devices recorded the minimum ‘valid’ data (Table 2). 
Results for the number of devices returned with any data, the number of devices returned 
with valid data and the mean duration of daily wear time is shown in Table 2. Preference for 
the GENEActiv device was reflected in greater wear time compared with the Actigraph 
device (mean wear time 1354 minutes per day vs 1079 minutes per day, p = 0.001). A higher 
number of GENEActiv devices recorded valid data over the wear period, both at the 
minimum threshold (91.7% vs 75%) and higher threshold (75% vs 58.3%). A greater number 
of complete 24 hour wear periods were recorded within each 7 day period using the 
GENEActiv than the Actigraph device (5.1 vs. 3.7). 
Despite the devices being worn over two separate periods rather than at the same time, the 
average output from the devices across 24 hours (ENMO), during the least active 5 hours 
(L5) and most active 5 hours (M5) showed no significant differences between devices (Table 
3). Time spent in MVPA, using both bout and non-bout criteria, was higher when measured 
by the GENEActiv devices compared with the actigraph devices. Although this was not 
statistically significant, the magnitude of difference between the two devices was large with 
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over two hours more MVPA recorded by the GENEActiv device over the course of a week 
where participants had valid data for both devices. In total, only three participants met 
World Health Organization (WHO) recommendations on time in MVPA per week according 
to ‘bout’ criteria (MVPA10). 
From the GENEActiv data, participants spent 427.3 minutes per day in sedentary behaviour; 
over half of their awake time. The mean time spent within each activity threshold per day 
were 245.4 minutes in light activity, 118.1 minutes in moderate activity and 7.1 minutes in 
vigorous activity, although the time in vigorous activity was skewed because of a high 
outlying value. With the outlying value removed the mean time spent performing vigorous 
activity fell to 3.1 minutes per day. Correlations between FAS scores and time spent within 
activity thresholds are shown in Figure 2. Moderately strong associations were seen 
between FAS scores and time in sedentary behaviours (r = 0.554, p=0.077), and time in light 
activity (r = -0.585, p=0.059). Weaker correlation was seen between moderate activity (r=-
0.506, p=0.112) and FAS scores. 
 
Discussion 
This study sought to clarify the preferred device by patients with sarcoidosis. A clear 
preference was demonstrated for the GENEActiv device, with the difference in scores on the 
VAS statistically significant across all domains. Comments received from participants 
suggested they disliked the size and the strap of the Actigraph. The design of the GENEActiv 
appeared more comfortable, although feedback suggested that participants would have 
liked a watch face to negate needing to wear both a watch and the accelerometer. Overall, 
the GENEActiv appeared much less intrusive, with participants noting reduced awareness of 
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the device with less interference with normal activity. This should provide a better reflection 
of daily activity through increased wear-time (which was seen in our results) and less 
disruption of normal daily activities. The high levels of wear time achieved from these 
devices is in keeping with benefits seen elsewhere; large population studies investigating 
activity, including the UK Biobank and NHANES, have switched from hip-worn 
accelerometers to wrist-worn devices due to increased wear time(26). Our results show that 
significant differences in wear time exist even within devices worn at the same location and 
reinforce the importance of choosing a device which is acceptable to the participants who 
will be wearing them. 
The preferred device in this study, the GENEActiv, had a mean daily non-wear time of only 
86 minutes per day averaged over the entire wear period. The ideal minimum wear time per 
day is debated with a number of different recommendations for valid wear time of 
accelerometers proposed. Our minimum validity definition was taken from previous 
recommendations(27). Other reviews and studies have suggested that 13 hours(28) or 16 
hours(21) are preferable to achieve an accurate picture of daily activity. Part of the rationale 
for these definitions was based on how sleep would impact on measurements due to 
difficulty separating sleep from periods of low activity (29). Modern accelerometry-based 
activity monitors, such as those tested here, incorporate additional sensors into the device 
(temperature and light sensing) which can be analysed with accelerometer outputs to 
determine sleep periods(30). These complex sensor arrangements allow sleep time and 
non-wear time to be excluded from activity analysis, meaning these devices can be truly “fit 
and forget” for participants in these trials. This also gives the option of collecting data on 
sleep patterns in addition to activity levels.  
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We investigated if there was correlation between fatigue measured by FAS scores and time 
in activity thresholds. Previous studies looking at fatigue and sarcoidosis have used clinic-
based measures of exercise capacity such as the six-minute walk test as predictors for 
fatigue, which have been shown to be poor at predicting fatigue scores (31, 32). Conversely, 
activity in free-living was shown to be affected by fatigue in one study of patients with 
sarcoidosis(13). In the small number of subjects monitored here, time spent in light activity 
strongly moderately correlated with FAS scores. Additionally, time in sedentary behaviours, 
which has not previously been investigated, showed association with FAS scores. This 
suggests that changes in fatigue may be reflected in changes in activity and sedentary 
behaviours. Assessment of larger cohorts of patients with sarcoidosis will help to confirm 
these associations, as well as whether a relationship exists between fatigue and moderate 
or vigorous activity. Furthermore, investigation into whether increasing a patient’s activity 
levels reduces their fatigue scores could be made using devices such as the ones used here. 
The results identified a clear preference between two of the most widely used devices, 
identifying the GENEActiv as an appropriate device for future studies investigating elements 
of activity behaviours in patients with sarcoidosis. The strong bivariate relationship between 
fatigue and both sedentary time and light activity time recorded by the GENEActiv was 
notable, especially given the small sample, and suggests that fatigue and activity may be 
closely linked.  The small sample size prevents conclusions being made regarding the 
relative impact of other factors such as lung function, use of immunosuppression or pattern 
of organ involvement have on activity levels. Future research in larger cohorts will be able to 
further investigate the effect these factors play in daily activity and sedentary behaviours in 
sarcoidosis. 
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Table 1 – Participant Characteristics 
 
Age – years (S.D.) 54.5 (13.0) 
Male gender (%) 7 (58.3) 
BMI – kg/m2 (%) 27.3 (4.7) 
Years since diagnosis (S.D.) 8.9 (8.7) 
Pulmonary disease (%) 12 (100) 
Extra-pulmonary disease (%) 
- Cardiac 
- Cutaneous 
- Ophthalmological 
5 (41.7) 
- 2 
- 2 
- 1 
On immunosuppression (%) 
- Prednisolone 
- Methotrexate 
- Azathioprine 
- Methylphenidate 
5 (41.7) 
- 4 
- 1 
- 1 
- 1 
FEV1 – % predicted (S.D.) 78.9 (23.2) 
FVC – % predicted (S.D.) 74.8 (40.5) 
Ratio (S.D.) 75.1 (16.6) 
Fatigue Assessment Scale (FAS) Score (S.D.) 
- FAS >21 (%) 
28.8 (9.3)  
- 9 (75) 
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Table 2 - Number of devices capturing data, including valid data, and total wear time by device 
 
 Actigraph GENEActiv p-value for diff 
No. devices returned with any 
data captured (%) 
9 (75%) 11 (91.7%) 0.197 
Number of devices with 
minimum valid data* (%) 
9 (75%) 11 (91.7%) 0.685 
Number of devices with 
higher valid data† (%) 
7 (58.3%) 9 (75%) 0.504 
Number of full 24h periods 
recorded (S.D.) 
3.7 (2.3) 5.1 (1.8) 0.150 
Wear time/day – min (S.D.) 1079 (215) 1354 (102) 0.001 
* More than 10 hours data for 2 weekdays and 2 weekend days 
† More than 16 hours data for 2 weekdays and 2 weekend days 
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Table 3 - Device outputs  
 
 Actigraph GENEActiv Within-patient 
magnitude of 
difference* 
ENMO – milli-g (S.D.) 25.7 (6.3) 27.4 (7.7) 1.24 (6.8) 
L5 – milli-g (S.D.) 4.2 (2.7) 4.3 (2.2) 0.62 (1.8) 
M5 – milli-g (S.D.) 48.5 (15.0) 51.3 (17.2) 3.19 (9.9) 
MVPA (week) – min (S.D.) 556.9 (308.4) 668.1 (345.2) 148.2 (239.8) 
MVPA10 (week) - min (S.D.) 56.1 (62.0) 72.2 (74.8) 30.4 (38.2) 
*Where paired data available; 8 participants provided data from both devices 
ENMO – Euclidean Norm Minus One-g (mean accelerometer output over 24 hour period) 
L5 – Mean accelerometer output (in milli-g) during the least active 5 hour period per day, averaged across all valid days 
M5 - Mean accelerometer output (in milli-g) during the most active 5 hour period per day, averaged across all valid days 
MVPA – Moderate or Vigorous Physical Activity using 100milli-g cut-off; no bout criteria used 
MVPA10 – Moderate or Vigorous Physical Activity using 100milli-g cut-off; bout criteria of 80% of any 10 minute block spent 
above 100milli-g threshold used 
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Figure 1 – Box-whisker plots of Visual Analogue Scale scores for experience of Actigraph and 
GENEActiv devices. 
 
 
 
  
* 
* 
* 
* * = p<0.05 
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Figure 2 - Correlation of Fatigue Assessment Scale score and time spent in activity thresholds from 
GENEActiv data 
  r = 0.554 
p = 0.077 
r = -0.585 
p = 0.059 
r = -0.506 
p = 0.112 
r = -0.210 
p = 0.535 
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